Product Description
a monotherapy in participants with newly diagnosed or recurrent epidermal growth factor receptor variant III (EGFRvIII)-positive glioblastoma (GBM). (Sourced from: https://www.clinicaltrials.gov/ct2/show/NCT05187624)
Mechanisms of Action: EGFR Inhibitor,CD3 Inhibitor
Novel Mechanism: No
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Hoffmann-La Roche
Company Location: BASEL SWITZERLAND V8
Company CEO: Severin Schwan
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Australia, Canada, Denmark, Netherlands, Spain, United States
Active Clinical Trial Count: 1
Highest Development Phases
Phase 1: Glioblastoma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| BP42573 | P1 |
Recruiting |
Glioblastoma |
2025-12-31 |
43% |